Founded in October 2015 by Chinese genomicist Jun Wang, former CEO of Beijing Genomic Institute (BGI), iCarbonX was touted as the "next Google in biotech". The company has raised $366M in funding over 5 rounds and is valued at $1B, positioning itself as a data aggregator leveraging BGI's world-class genomics heritage to build an ecosystem combining AI, multi-omics analysis, and personalized health solutions for global markets.
Cyborg Score Rationale
iCarbonX possesses exceptional technical pedigree through BGI founders, achieved unicorn status rapidly, and has built a differentiated multi-omics + AI platform. However, the company remains private with no public funding announcements since April 2021, lacks recent commercial traction data, and operates in a highly competitive precision medicine space with regulatory complexities.
Top Insights
iCarbonX is a mega aggregator of health data, having specifically focused on US-based health data and personalized medicine startups, likely driven by the lack of organized, digitized patient health records in China and the company's plans for expansion in countries including the United States
iCarbonX is harnessing AI, genomics, and data analytics to advance personal health insights and has developed four diagnostic pipelines covering autoimmune diseases, allergy-related antigen testing, infectious disease detection, and cancer biomarkers
The company is taking an Amazon-for-health approach, with its platform functioning as an ecosystem of health services rather than a singular product
iCarbonX launched its Digital Life Alliance in January 2017 with seven companies including SomaLogic, HealthTell, and PatientsLikeMe
Named Competitors
Lifebit — Genomic data analysis and precision medicine platform
Cellworks — Systems biology and drug development platform
Immuneering Corporation — Immunology and precision medicine solutions
Human Longevity — Personalized genomics and longevity research
Wuxi NextCODE — Genomic data analysis and precision medicine
Recent Developments
(April 2021) Series D funding round of $151M led by China Money Network and China Investment Corporation
(August 2025) Company advancing AI-driven drug development and developing AI-powered health avatars alongside diagnostic pipelines
No major funding or partnership announcements disclosed since April 2021
Open the full interactive iCarbonX report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.